![]() |
|
|
Vol. 302, Issue 2, 584-593, August 2002
-Estradiol-3-benzoate
Faculty of Pharmaceutical Sciences, University of British Columbia,
Vancouver, British Columbia, Canada
Tamoxifen, a nonsteroidal antiestrogen, is used widely in the treatment
of breast cancer and is undergoing evaluation as a chemopreventive
agent. In this study, we investigated several long-term effects of
tamoxifen in intact adult female rats following acute treatment at
various dosages. The effects of tamoxifen on somatic growth, growth
hormone (GH) levels, thyroid hormone levels, and on hepatic cytochrome
P450 (P450) expression were compared with those of
fulvestrant (ICI 182,780), 17
-estradiol-3-benzoate, and
4-hydroxytamoxifen under the same experimental conditions. Each
compound was injected s.c. for two consecutive days, and rats were
killed 37 days after treatment. Tamoxifen decreased body weight and
serum triiodothyronine (T3) levels at dosages ranging from 0.5 to 200 mg/kg. Ovary weight, uterus weight, peak plasma GH concentration, and
hepatic CYP2A1 content were decreased 37 days after treatment with
tamoxifen at a dosage of 20 mg/kg, but expression of other P450 enzymes
was not affected. However, tamoxifen and 4-hydroxytamoxifen could not
be detected in plasma by high performance liquid chromatography
analysis at this time, which suggests that the effects of tamoxifen
were mediated indirectly. 4-Hydroxytamoxifen exhibited effects similar
to those of tamoxifen, indicating that this metabolite contributes to
the in vivo activity of tamoxifen. Estradiol benzoate decreased CYP2A1
and increased CYP3A hepatic levels, but had no effect on serum T3
concentration. In contrast, treatment with ICI 182,780 had little or no
effect on the endpoints measured. In summary, 2-day tamoxifen treatment of intact adult female rats resulted in persistent suppression of
somatic growth, serum T3 levels, and hepatic CYP2A1 expression.